Brought to you by:
Results from PROMISE II pivotal trial published, reinforcing ‘ transformational value’ of deep vein arterialization in no-option CLTI patients
Results from the PROMISE II pivotal trial investigating transcatheter arterialization of the deep veins using the LimFlow system in so-called no-option chronic limb-threatening ischemia (CLTI) patients were today published in the New England Journal of Medicine (NEJM). The publication confirmed…
SCVS 2023: Endovascular-first or -only approach to all CLTI patients ‘is not evidence-based care’
Michael S. Conte, MD, one of the foremost experts in the field of peripheral arterial disease (PAD), took attendees of the 2023 annual meeting of the Society for Clinical Vascular Surgery (SCVS) in Miami on a journey through the decades…
Florida hospital targets lingering disparities in limb salvage with region’s first multidisciplinary Limb Preservation Program
This advertorial is sponsored by Tampa General Hospital. Operating in Tampa, Florida, Charles J. Bailey, MD, and his partners in the Division of Vascular Surgery at the University of South Florida see their fair share of preventable amputations. In a…
Shockwave Medical announces US launch of new peripheral IVL catheter
Shockwave Medical announced the full U.S. commercial availability of the Shockwave L6 peripheral intravascular lithotripsy (IVL) catheter following clearance by the Food and Drug Administration (FDA). A press release details that the Shockwave L6 catheter is purpose-built to modify calcification in otherwise difficult-to-treat…
New VOYAGER PAD analysis confirms consistent benefit of low-dose rivaroxaban plus aspirin following lower extremity revascularization
Data from a new prespecified analysis of the phase III VOYAGER PAD clinical trial show that low-dose rivaroxaban plus aspirin resulted in a 33% reduction in acute limb ischemia and a 15% reduction in major adverse limb and cardiovascular events,…
‘Urgent action needed’ to improve implementation of guideline-directed medical therapy for PVI
Almost one-half of the patients receiving a peripheral vascular intervention (PVI) in the Society for Vascular Surgery (SVS) Vascular Quality Initiative (VQI) registry between 2017 and 2018 were not on guideline-directed medical therapy (GDMT). Kim G. Smolderen, PhD, and Carlos…
More than a research project: The vascular trainee’s role in tackling disparities in peripheral arterial disease
One of my earliest clinical experiences with vascular disease was as a high school student shadowing at a busy urban hospital in Detroit. A Black man with a longstanding history of diabetes developed a foot ulcer that ultimately required an…
The top 10 most popular Vascular Specialist stories of January 2023
In January 2023, most popular among the Vascular Specialist readers were several stories from the recent Southern Association for Vascular Surgery meeting, including a report of data shared to demonstrate the benefits of vascular involvement in non-vascular-led cases; an update on the use of the Human Acellular…
Patients with claudication receive more ‘aggressive’ surgical management in high-competition regions, study finds
Demonstrating the “susceptibility” of care delivery to regional market competition, M. Libby Weaver, MD, presented the case that intermittent claudication (IC) is a “novel and underdefined” driver of practice variation in management of patients at the 2023 Southern Association for…
VQI study leader highlights virtue of multispecialty gathering of best longitudinal data on PAD procedures
Daniel Bertges, MD, talks to Vascular Specialist about recent findings from his work investigating the IN.PACT Admiral drug-coated balloon (DCB). He related how they showed promising results in treating femoropopliteal in-stent restenosis in a Society for Vascular Surgery (SVS) Vascular…